3-(N-tert-butyloxycarbonylamino)-4-hydroxy benzylbutyrate | 220389-06-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(N-tert-butyloxycarbonylamino)-4-hydroxy benzylbutyrate
• 英文别名: benzyl 3-t-butoxycarbonylamino-4-hydroxybutanoate；3-N-tBoc-amino-4-hydroxy-butyric acid benzyl ester；benzyl 4-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate
• CAS: 220389-06-0
• 化学式: C₁₆H₂₃NO₅
• 分子量: 309.362
• InChiKey: XEGSFNZVTUGZCK-UHFFFAOYSA-N

物化性质

• 沸点：
  467.4±45.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(N-tert-butyloxycarbonylamino)-4-hydroxy benzylbutyrate 在 咪唑 、 diphenylphosphinopolystyrene 、 碘 、 sodium carbonate 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 7.5h， 生成 3-(N-fluorenylmethoxycarbonylamino)-4-cyano benzylbutyrate
  参考文献：
  名称：

  Synthesis and conformation of dipeptide taste ligands containinghomo-β-amino acid residues

  摘要：

  The synthesis and conformational properties of a series of dipeptide taste ligands, differing from the commercial sweetener aspartame by the presence of a methylene group between the C-alpha and the C' carbon atoms (as in homo-beta-residues) in either the L-Asp or the L-Phe residues, are described. Homo-beta-residues such as homo-beta-aspartic acid, homo-beta-phenylglycine and homo-beta-phenylalanine, obtained by homologation of the corresponding proteinogenic alpha-amino acids, have been used in the solution peptide synthesis of the following aspartame analogues in protected and unprotected forms: NH2-homo-beta-(L or D)-Asp-L-Phe-OMe, NH2-L-Asp-homo-beta-L-Phg-OMe and NH2-L-Asp-homo-beta-L-Phe-OMe. Lengthening of the peptide skeleton at the L-Asp site results in a drastic loss of sweetness with the production of tasteless compounds; on the other hand, lengthening of the skeleton at the C-terminal L-Phe site partially mantains the sweet taste in both NH2-L-Asp-homo-beta-L-Phe-OMe and NH2-L-Asp-homo-beta-L-Phg-OMe. The solution conformation of the synthesized dipeptide taste ligands was investigated by NMR and circular dichroism techniques. The analysis of NMR data combined with restrained molecular dynamics calculations shows that all peptides are fairly flexible and they do not assume a preferred conformation in DMSO and methanol. The peptides containing homo-beta-L-Phe and homo-beta-L-Phg do adopt a discrete number of conformations among which mainly extended and 'L-shaped' conformation are represented. The circular dichroism spectra are consistent with the NMR results, indicating a significant flexibility for these compounds. Copyright (C) 1999 John Wiley & Sons, Ltd.

  DOI：

  10.1002/(sici)1099-1395(199907)12:7<577::aid-poc159>3.0.co;2-f
• 作为产物：
  描述：

  Boc-L-天冬氨酸 4-苄酯 在 N-甲基吗啉 、 sodium tetrahydroborate 、 氯甲酸甲酯 作用下， 以 四氢呋喃 为溶剂， 以84%的产率得到3-(N-tert-butyloxycarbonylamino)-4-hydroxy benzylbutyrate
  参考文献：
  名称：

  Synthesis and conformation of dipeptide taste ligands containinghomo-β-amino acid residues

  摘要：

  The synthesis and conformational properties of a series of dipeptide taste ligands, differing from the commercial sweetener aspartame by the presence of a methylene group between the C-alpha and the C' carbon atoms (as in homo-beta-residues) in either the L-Asp or the L-Phe residues, are described. Homo-beta-residues such as homo-beta-aspartic acid, homo-beta-phenylglycine and homo-beta-phenylalanine, obtained by homologation of the corresponding proteinogenic alpha-amino acids, have been used in the solution peptide synthesis of the following aspartame analogues in protected and unprotected forms: NH2-homo-beta-(L or D)-Asp-L-Phe-OMe, NH2-L-Asp-homo-beta-L-Phg-OMe and NH2-L-Asp-homo-beta-L-Phe-OMe. Lengthening of the peptide skeleton at the L-Asp site results in a drastic loss of sweetness with the production of tasteless compounds; on the other hand, lengthening of the skeleton at the C-terminal L-Phe site partially mantains the sweet taste in both NH2-L-Asp-homo-beta-L-Phe-OMe and NH2-L-Asp-homo-beta-L-Phg-OMe. The solution conformation of the synthesized dipeptide taste ligands was investigated by NMR and circular dichroism techniques. The analysis of NMR data combined with restrained molecular dynamics calculations shows that all peptides are fairly flexible and they do not assume a preferred conformation in DMSO and methanol. The peptides containing homo-beta-L-Phe and homo-beta-L-Phg do adopt a discrete number of conformations among which mainly extended and 'L-shaped' conformation are represented. The circular dichroism spectra are consistent with the NMR results, indicating a significant flexibility for these compounds. Copyright (C) 1999 John Wiley & Sons, Ltd.

  DOI：

  10.1002/(sici)1099-1395(199907)12:7<577::aid-poc159>3.0.co;2-f

文献信息

• N-acylamino acid amide compounds and intermediates for preparation thereof
  申请人：Ube Industries, Ltd.

  公开号：US06265418B1

  公开（公告）日：2001-07-24

  The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.

  本发明公开了以下公式（I）所表示的化合物： 其中A代表以下公式（a-1）或以下公式（a-2）： B代表以下公式（b）： （其中符号如规范中所定义）或其药学上可接受的盐，以及用于制备其的中间体，具有优异的血小板聚集抑制活性和其他性质，并且可用作与纤维蛋白原受体、血栓形成、梗塞等疾病相关的预防或治疗剂。
• [EN] 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES<br/>[FR] DERIVES D'AZETIDINE 1, 3-DISUBSTITUES A UTILISER EN TANT QU'ANTAGONISTES DU RECEPTEUR CCR3 DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES ET ALLERGIQUES
  申请人：NOVARTIS AG

  公开号：WO2005026113A1

  公开（公告）日：2005-03-24

  Compounds of formula Ia or Ib in free or salt form, wherein Ar, X1, X2, m, R1, Q, Y, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by CCR-3, for example an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式Ia或Ib的化合物，无论是自由形式还是盐形式，其中Ar、X1、X2、m、R1、Q、Y、R2和R3的含义如规范中所示，可用于治疗由CCR-3介导的疾病，例如炎症或过敏症状，特别是炎症或阻塞性气道疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF
  申请人：Novartis AG

  公开号：US20130225574A1

  公开（公告）日：2013-08-29

  The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

  本发明涉及氧唑烷-2-酮取代嘧啶化合物，其作为PI3K（磷脂酰肌醇-3-激酶）抑制剂，以及其药物组合物、制备方法和用于治疗依赖于PI3K的疾病、病症和疾病的用途。
• [EN] IMPROVED APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF<br/>[FR] AGONISTES AMÉLIORÉS DU RÉCEPTEUR DE L'APÉLINE (APJ) ET LEURS UTILISATIONS
  申请人：RES TRIANGLE INST

  公开号：WO2017100558A1

  公开（公告）日：2017-06-15

  This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

  这项披露涉及到阿普林受体（APJ）的激动剂以及这些激动剂的用途。
• Lactone integrin antagonists
  申请人：——

  公开号：US20020045645A1

  公开（公告）日：2002-04-18

  The present invention relates to a class of compounds represented by the Formula I. 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr; v &bgr; 3 and/or the &agr; v &bgr; 5 integrin.

  本发明涉及一类由式I.1表示的化合物，或其药学上可接受的盐，包括式I的化合物的药物组合物，以及选择性地抑制或拮抗αvβ3和/或αvβ5整合素的方法。